Alnuctamab双价BCMA靶向T细胞衔接器治疗复发难治多发性骨髓瘤的I期首次人体研究
Alnuctamab是一种靶向BCMA和CD3ε的双特异性抗体,I期剂量递增/扩展研究纳入≥3线治疗且BCMA靶向初治的复发难治多发性骨髓瘤患者。皮下给药推荐II期剂量为30 mg,总体客观缓解率58.9%,30 mg队列为71.4%,49.5%患者MRD阴性。安全性与其他BCMA靶向疗法相当,皮下给药安全性优于静脉给药,逐步剂量递增策略可减轻CRS。
要点
- 皮下Alnuctamab推荐II期剂量30 mg,总体ORR 58.9%,30 mg队列ORR 71.4%。
- 49.5%患者达到MRD阴性,CRS发生率57.9%但无3/4级事件。
- 皮下给药安全性优于静脉给药,逐步剂量递增策略可减轻CRS。
核心结论
- 皮下Alnuctamab在复发难治多发性骨髓瘤中显示出与其它BCMA靶向疗法相当的安全性和疗效。
- 皮下给药安全性优于静脉给药,逐步剂量递增策略可减轻细胞因子释放综合征。
研究设计与样本
- CC-93269-MM-001是一项首次人体、I期剂量递增/扩展研究,评估Alnuctamab在复发难治多发性骨髓瘤中的安全性和疗效。
- 患者需≥3线既往治疗、末次治疗后≤60天疾病进展且BCMA靶向治疗初治;95例患者接受皮下Alnuctamab,数据截止时44.2%仍在治疗,中位随访8.0个月。
主要发现
- 最常见治疗中出现的不良事件(任何级别/3-4级)为CRS(57.9%/0%)和中性粒细胞减少(53.7%/43.2%),感染也常见(64.2%/14.7%)。
- 全部皮下治疗患者ORR为58.9%,30 mg队列为71.4%;47/95(49.5%)患者MRD阴性。
关键数值与推荐
- 推荐II期剂量为30 mg皮下给药。
- ORR在全部皮下治疗患者中为58.9%,在30 mg队列中为71.4%。
- MRD阴性率为49.5%(47/95)。
临床怎么用
- 皮下Alnuctamab可采用逐步剂量递增策略以减轻CRS,推荐II期剂量为30 mg。
- 随时间减弱的给药方案可能提供更有利的毒性特征,或可适用于其他双特异性衔接器。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell maturation antigen (BCMA)-targeting therapies provide a new approach to treating multiple myeloma (MM). Alnuctamab (ALNUC) is a 2 + 1 immunoglobulin G1-based bispecific antibody binding BCMA and CD3ε receptors on myeloma and T cells, respectively. CC-93269-MM-001 is a first-in-human, phase 1 dose escalation/expansion study investigating ALNUC in relapsed/refractory MM. Patients had ≥3 prior regimens, disease progression ≤60 days of last regimen, and were BCMA-directed therapy-naïve. ALNUC was administered intravenously (IV) and subcutaneously (SC); however, SC was selected for further evaluation due to the more favorable safety profile. Ninety-five patients received ALNUC SC; at data cutoff, 44.2% remained on treatment and median follow-up was 8.0 months. The recommended phase 2 dose was 30 mg. The most common treatment emergent adverse events (any grade/grade 3/4) were CRS (57.9%/0%), and neutropenia (53.7%/43.2%). Infections were also frequent (64.2%/14.7%). ORR was 58.9% for all ALNUC SC-treated patients and 71.4% for the 30-mg cohort; 47/95 (49.5%) were measurable residual disease (MRD) negative. Overall, the safety and efficacy of ALNUC SC were comparable to other BCMA-targeted therapies. These results support improved safety of SC versus IV, and corroborate a step-up dosing strategy to mitigate CRS. Importantly, a schedule that de-intensifies over time provides favorable toxicity that may be applicable to other bispecific engagers.
引用
- Bar N, Martin T, Hofmeister CC, et al. Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study. Leukemia. 2026. PMID: 41501501. doi:10.1038/s41375-025-02841-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。